<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="643">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864006</url>
  </required_header>
  <id_info>
    <org_study_id>2006-1294</org_study_id>
    <nct_id>NCT00864006</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions</brief_title>
  <official_title>A Single-Dose, Comparative Bioavailability Study of Two Formulations of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the bioequivalence of divalproex sodium 125 MG
      delayed release tablets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Bioequivalence according to US FDA Guidelines</measure>
    <time_frame>9 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Divalproex Sodium 125 MG Delayed Release Tablets Sandoz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Depakote 125 MG DR Tablets Abbott Laboratories USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex Sodium</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depakote DR Tablets</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No clinically significant findings on physical examination, medical history or
             laboratory tests on screening

        Exclusion Criteria:

          -  Positive test for HIV or Hepatitis B and C

          -  History of sensitivity to valproic acid or related compounds
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xueyu Chen, MD, Ph.D, FRCP(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharma Medica Research, Inc.</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <lastchanged_date>March 17, 2009</lastchanged_date>
  <firstreceived_date>March 17, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Eric Mitleberg. Ph.D., VP Product Development</name_title>
    <organization>Sandoz, Inc.</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
